United Therapeutics Corporation (UTHR)

NasdaqGS Currently down 5.27 (-0.94%) in today's trading session

1 member of Congress has disclosed 4 trades in United Therapeutics Corporation (UTHR) via STOCK Act filings. The most recent disclosure was a sale by Lisa McClain on 31 October 2025. Aggregate disclosed activity totals roughly $16K in purchases and $16K in sales (midpoint estimates from bracketed disclosure amounts).

United Therapeutics Corporation is currently trading at $556.82, positioned at 84% of its 52-week range ($272.12 – $609.35).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$556.82
24h Change
-5.27 (-0.94%)
52 Week Range
$272.12$609.35
View on NASDAQ

United Therapeutics Corporation Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for UTHR

Select to highlight on chart
3 transactions
Compliance: 75%
Lisa McClain31 Oct 202521 Nov 2025SaleStock$1,001 - $15,000N/A
Lisa McClain30 Oct 202521 Nov 2025SaleStock$1,001 - $15,000N/A
Lisa McClain30 Oct 202521 Nov 2025PurchaseStock$1,001 - $15,000+22.29%

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$23.64B

Volume

537.09K

Beta

0.59

P/E Ratio

20.58

Fundamentals

EPS

$27.05

Div. Yield

Open

$562.74

Day Range

$548.12 — $562.74

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Martine A. Rothblatt
IPO Date
1999-06-17

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally....

Earnings

Next Report

Q2 2026

29 Jul

EPS Est.

$7.17

Rev. Est.

$810.4M

Days Until

60

Recent Quarters

Q1 20266 May
EPS$5.82
Miss 16.9%
Q4 202525 Feb
EPS$7.70
Beat 8.0%
Q3 202529 Oct
EPS$7.16
Beat 3.9%
Q2 202530 Jul
EPS$6.41
Miss 12.1%
Q1 202530 Apr
EPS$6.63
Beat 5.4%
Q4 202426 Feb
EPS$6.19
Miss 3.3%
Q3 202430 Oct
EPS$6.39
Miss 0.6%
Q2 202431 Jul
EPS$5.85
Miss 8.6%
Q1 20241 May
EPS$6.17
Beat 9.2%
Q4 202321 Feb
EPS$4.36
Beat 4.1%
Q3 20231 Nov
EPS$5.38
Beat 6.8%
Q2 20232 Aug
EPS$5.24
Beat 16.2%
Q1 20233 May
EPS$4.86
Beat 7.5%
Q4 202222 Feb
EPS$2.67
Miss 40.8%
Q3 20222 Nov
EPS$4.91
Beat 26.2%
Q2 20223 Aug
EPS$2.41
Miss 41.6%
Q1 20224 May
EPS$5.03
Beat 50.1%
Q4 202124 Feb
EPS$2.35
Miss 36.8%
Q3 20213 Nov
EPS$3.42
Miss 4.7%
Q2 20214 Aug
EPS$3.65
Beat 20.9%
Q1 20215 May
EPS$0.61
Miss 79.3%
Q4 202024 Feb
EPS$2.19
Miss 30.3%
Q3 202028 Oct
EPS$3.86
Beat 36.4%
Q2 202029 Jul
EPS$2.41
Miss 16.0%
Q1 202029 Apr
EPS$3.12
Beat 13.4%
Q4 201926 Feb
EPS$1.20
Miss 55.2%
Q3 201930 Oct
EPS$3.16
Beat 29.5%
Q2 201931 Jul
EPS$4.11
Beat 65.1%
Q1 20191 May
EPS$3.58
Beat 35.6%
Q4 201827 Feb
EPS$3.34
Beat 31.5%
Q3 201831 Oct
EPS$3.98
Beat 14.0%
Q2 20181 Aug
EPS$3.98
Beat 25.6%
Q1 20182 May
EPS$3.76
Miss 8.3%
Q4 201721 Feb
EPS$3.89
Beat 3.2%
Q3 201725 Oct
EPS$6.27
Beat 62.0%
Q2 201727 Jul
EPS$-1.25
Miss 134.6%
Q1 201726 Apr
EPS$3.89
Beat 17.5%
Q4 201622 Feb
EPS$2.49
Miss 31.0%
Q3 201627 Oct
EPS$3.50
Beat 4.8%
Q2 201628 Jul
EPS$4.39
Beat 36.3%
Q1 201628 Apr
EPS$4.84
Beat 50.8%
Q4 201525 Feb
EPS$2.10
Miss 17.6%
Q3 201527 Oct
EPS$3.55
Beat 45.5%
Q2 201528 Jul
EPS$1.91
Miss 17.3%
Q1 201528 Apr
EPS$2.55
Beat 21.4%
Q4 201424 Feb
EPS$2.37
Beat 16.8%
Q3 201428 Oct
EPS$3.91
Beat 112.5%
Q2 201429 Jul
EPS$2.10
Beat 20.0%
Q1 201429 Apr
EPS$1.57
Beat 0.0%
Q4 201325 Feb
EPS$2.88
Beat 70.4%
Q3 201329 Oct
EPS$1.17
Miss 26.4%
Q2 201325 Jul
EPS$1.52
Beat 3.4%
Q1 201325 Apr
EPS$1.19
Miss 19.1%
Q4 201226 Feb
EPS$1.60
Beat 28.0%
Q3 20121 Nov
EPS$1.46
Beat 16.8%
Q2 201226 Jul
EPS$1.34
Beat 19.6%
Q1 201226 Apr
EPS$1.29
Beat 38.7%
Q4 201114 Feb
EPS$0.77
Miss 11.5%
Q3 201127 Oct
EPS$1.32
Beat 80.8%
Q2 201128 Jul
EPS$1.18
Beat 122.6%
Q1 201128 Apr
EPS$0.26
Miss 59.4%
Q4 201015 Feb
EPS$0.15
Miss 75.8%
Q3 201028 Oct
EPS$0.66
Beat 22.2%
Q2 201028 Jul
EPS$0.62
Beat 37.8%
Q1 201029 Apr
EPS$0.32
Beat 10.3%
Q4 200916 Feb
EPS$-0.06
Miss 121.4%
Q3 200929 Oct
EPS$0.21
Miss 30.0%
Q2 200931 Jul
EPS$-0.04
Miss 114.8%
Q1 20091 May
EPS$0.25
Miss 19.4%
Q4 200817 Feb
EPS$-1.71
Miss 757.7%
Q3 200830 Oct
EPS$0.25
Miss 13.8%
Q2 200831 Jul
EPS$0.30
Beat 3.5%
Q1 20081 May
EPS$0.24
Miss 11.1%
Q4 200719 Feb
EPS$0.04
Miss 81.8%
Q3 20071 Nov
EPS$0.33
Beat 94.1%
Q2 200731 Jul
EPS$0.13
Miss 27.8%
Q1 20071 May
EPS$0.22
Miss 26.7%
Q4 200620 Feb
EPS$0.38
Beat 8.6%
Q3 200631 Oct
EPS$0.37
Beat 42.3%
Q2 20061 Aug
EPS$0.34
Beat 70.0%
Q1 20062 May
EPS$0.20
Miss 16.7%
Q4 200521 Feb
EPS$0.57
Beat 72.7%
Q3 200531 Oct
EPS$0.31
Beat 29.2%
Q2 20052 Aug
EPS$0.25
Beat 56.3%
Q1 20053 May
EPS$0.16
Beat 14.3%
Q4 200422 Feb
EPS$0.14
Beat 40.0%
Q3 20043 Nov
EPS$0.14
Beat 75.0%
Q2 20043 Aug
EPS$0.09
Q1 20046 May
EPS$-0.04
Miss 285.7%
Q4 200324 Feb
EPS$-0.07
Miss 106.9%
Q3 20036 Nov
EPS$-0.03
Miss 29.4%
Q2 20035 Aug
EPS$-0.05
Beat 0.0%
Q1 20036 May
EPS$-0.07
Beat 22.2%
Q4 200225 Feb
EPS$-0.06
Beat 25.0%
Q3 200214 Nov
EPS$-0.29
Q3 20028 Nov
EPS$-0.14
Beat 12.5%
Q1 200214 May
EPS$-0.14
Q4 200120 Mar
EPS$-0.18
Q3 20019 Nov
EPS$-0.24
Q2 200110 Aug
EPS$-0.26
Miss 8.3%
Q1 20019 May
EPS$-0.23
Beat 0.0%
Q4 200021 Mar
EPS$-0.29
Miss 16.0%
Q3 20002 Nov
EPS$-0.17
Beat 37.0%
Q2 20009 Aug
EPS$-0.24
Beat 0.0%
Q1 20009 May
EPS$-0.22
Beat 4.3%
Q4 19992 Mar
EPS$-0.28
Beat 0.0%
Q3 199915 Nov
EPS$-0.20
Q3 19998 Nov
EPS$-0.20
Beat 23.1%
Q4 199831 Mar
EPS$-0.40

No dividend data available for this stock.

Stock Splits

Split History

23 Sept 2009Stock Split
Ratio2:1

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

PLTR

Palantir Technologies Inc.

20
$156.54+13.20 (+9.21%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

TSM

Taiwan Semiconductor Manufacturing Company Limited

20
$418.45-6.41 (-1.51%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

IVV

iShares Core S&P 500 ETF

17
$760.05+1.88 (+0.25%)
Financial Services
Held by same politician
1 politician
View Stock

Frequently Asked Questions about UTHR

Which members of Congress have traded UTHR?
1 member of Congress has disclosed 4 trade in United Therapeutics Corporation (UTHR) under the STOCK Act: Lisa McClain.
When was UTHR most recently disclosed by Congress?
The most recent UTHR disclosure was a sale by Lisa McClain on 31 October 2025.
What is the total disclosed congressional trading volume for UTHR?
Members of Congress have disclosed approximately $16K in UTHR purchases and $16K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in UTHR?
This UTHR page updates as soon as new STOCK Act disclosures are filed for United Therapeutics Corporation. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.